Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence

Francesco Patti, Francesco Patti

Abstract

Poor treatment adherence is problematic in many therapy areas, including multiple sclerosis (MS). Several immunomodulatory drugs are available for the treatment of MS, all of which require frequent parenteral administration. Current first-line therapies are two formulations of interferon (IFN) beta-1a, one of IFN beta-1b, and one of glatiramer acetate. Discontinuation of treatment is common, particularly in the first few months after initiation. Although the true effect of poor adherence to MS therapy is not known, it is likely to lead to a fall in treatment efficacy. Many factors influence a patient's adherence to treatment, including the patient's MS subtype and disability level, cognitive impairment resulting from MS, perceived lack of efficacy of the prescribed medication, and adverse events associated with MS therapy. This article summarizes the barriers to adherence to MS therapies, and discusses patient management strategies that can be employed to encourage adherence. Future advances in the field of MS treatment will be explored, including the development of orally administered drugs, which may enhance adherence.

Keywords: adherence; adverse events; compliance; efficacy; interruption; management; multiple sclerosis; tolerability.

Figures

Figure 1
Figure 1
Factors leading to poor adherence to multiple sclerosis therapy.

References

    1. World Health Org. Adherence to long-term therapies. URL: . Accessed Feb 26, 2007.
    1. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94:652–6561.
    1. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review. Manag Care Interface. 2006;19:31–41.
    1. Who gets MS? URL: . Accessed May 21, 2009.
    1. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability Brain 1989112(Pt 1):133–146.
    1. Gonsette RE. Mitoxantrone immunotherapy in multiple sclerosis. Mult Scler. 1996;1:329–332.
    1. Natalizumab SPC. URL: . Accessed Nov 29, 2007.
    1. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology. 2003;61:551–554.
    1. Mohr DC, Goodkin DE, Likosky W, Gatto N, Neilley LK, Griffin C, et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment. Mult Scler. 1996;2:222–226.
    1. Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Eur Neurol. 2008;59:131–135.
    1. Rio J, Porcel J, Tellez N, Sanchez-Betancourt A, Tintore M, Arevalo MJ, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler. 2005;11:306–309.
    1. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology. 1991;41:685–691.
    1. Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol. 1997;54:531–533.
    1. Clerico M, Barbero P, Contessa G, Ferrero C, Durelli L. Adherence to interferon-beta treatment and results of therapy switching. J Neurol Sci. 2007;259:104–108.
    1. Frohman E, Phillips T, Kokel K, Van Pelt J, O’Leary S, Gross S, et al. Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. Neurologist. 2002;8:227–236.
    1. Bayas A, Rieckmann P. Managing the adverse effects of interferon beta therapy in multiple sclerosis. Drug Saf. 2000;22:149–159.
    1. PRISMS Study Group, University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 2001;56:1628–1636.
    1. Kappos L, Traboulsee A, Constantinescu C, Eralinna JP, Forrestal F, Jongen P, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology. 2006;67:944–953.
    1. Avonex SPC. URL: . Accessed Nov 29, 2007.
    1. Betaferon SPC. URL: . Accessed Nov 29, 2007.
    1. Rebif SPC. URL: . Accessed Nov 29, 2007.
    1. Edgar CM, Brunet DG, Fenton P, McBride EV, Green P. Lipoatrophy in patients with multiple sclerosis on glatiramer acetate. Can J Neurol Sci. 2004;31:58–63.
    1. Soos N, Shakery K, Mrowietz U. Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis. Am J Clin Dermatol. 2004;5:357–359.
    1. Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology. 1999;53:1622–1627.
    1. Lesaux J, Jadback G, Harraghy CE. Improving the convenience of home-based interferon beta-1a therapy for multiple sclerosis. J Neurosci Nurs. 1999;31:174–179.
    1. Cox D, Stone J. Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. J Neurosci Nurs. 2006;38:167–171.
    1. Richter A, Anton SE, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther. 2003;25:2307–2335.
    1. O’Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler. 2005;11:46–50.
    1. Al-Sabbagh A, Bennet R, Kozma C, Dickson M, Meletiche D. Medication gaps in disease-modifying therapy for multiple sclerosis are associated with an increased risk of relapse: findings from a national managed care database. J Neurol. 2008;255(Suppl 2):S79.
    1. Mikol D, Lopez-Bresnahan M, Taraskiewicz S, Chang P, Rangnow J. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Mult Scler. 2005;11:585–591.
    1. Cramer JA, Cuffel BJ, Divan V, Al-Sabbagh A, Glassman M. Patient satisfaction with an injection device for multiple sclerosis treatment. Acta Neurol Scand. 2006;113:156–162.
    1. Rio J, Nos C, Bonaventura I, Arroyo R, Genis D, Sureda B, et al. Corticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trial. Neurology. 2004;63:525–528.
    1. Denis L, Namey M, Costello K, Frenette J, Gagnon N, Harris C, et al. Long-term treatment optimization in individuals with multiple sclerosis using disease-modifying therapies: a nursing approach. J Neurosci Nurs. 2004;36:10–22.
    1. Mohr DC, Goodkin DE, Masuoka L, Dick LP, Russo D, Eckhardt J, et al. Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis. Mult Scler. 1999;5:192–197.
    1. Glanz B, Holland C, Gauthier S, Amunwa E, Liptak Z, Houtchens M, et al. Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis. Mult Scler. 2007;13:1004–1010.
    1. Giovannoni G, Barbarash O, Casset-Semanaz F, King J, Metz L, Pardo G, et al. Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult Scler. 2009;15:219–228.
    1. Phillips JT, Rice G, Frohman E, Vande Gaer L, Scott T, Haas J, et al. A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis. Clin Ther. 2004;26:511–521.
    1. Bellary S, Barnett AH. Inhaled insulin (Exubera): Combining efficacy and convenience. Diab Vasc Dis Res. 2006;3:179–185.
    1. Fallowfield L, Atkins L, Catt S, Cox A, Coxon C, Langridge C, et al. Patients’ preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol. 2006;17:205–210.
    1. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110–115.
    1. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2(12):12–24.
    1. Reginster JY, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone. 2006;38:S2–S6.
    1. Clotet B, Carmena J, Pulido F, Luque I, Rodriguez-Alcantara F. Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients. HIV Clin Trials. 2004;5:33–39.
    1. Sleight P, Pouleur H, Zannad F. Benefits, challenges, and registerability of the polypill. Eur Heart J. 2006;27:1651–1656.
    1. Rau JL. Determinants of patient adherence to an aerosol regimen. Respir Care. 2005;50:1346–1356.
    1. Kruk ME, Schwalbe N. The relation between intermittent dosing and adherence: preliminary insights. Clin Ther. 2006;28:1989–1995.
    1. Yang JS, Xu LY, Xiao BG, Hedlund G, Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol. 2004;156:3–9.
    1. Kappos L, Miller D, MacManus DG, Gold R, Havrdova E, Limmroth V, et al. BG00012, a novel oral fumarate, is effective in patients with relapsing–remitting multiple sclerosis. Mult Scler. 2006;12(Suppl 1):P325.
    1. Kappos L, Antel J, Comi G, Montalban X, O’Connor P, Polman CH, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355:1124–1140.
    1. First Phase III results for FTY720, a novel oral therapy for MS, show superior efficacy compared to interferon beta-1a. URL: . Accessed Feb 10, 2009
    1. Zeyda M, Poglitsch M, Geyeregger R, Smolen JS, Zlabinger GJ, Horl WH, et al. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum. 2005;52:2730–2739.
    1. Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A. 1996;93:1716–1720.
    1. Soelberg-Sorensen P, Comi G, Cook S, Giovannoni G, Rammohan K, Rieckmann P, et al. Haematological profiles in patients treated with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS): results from the CLARITY study, a 96 week, phase III, double-blind, placebo-controlled trial. J Neurol. 2009;256:S127–S128.
    1. Chitnis T. The role of CD4 T cells in the pathogenesis of multiple sclerosis. Int Rev Neurobiol. 2007;79:43–72.
    1. Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R, et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med. 2000;192:393–404.
    1. Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology. 2000;54:1145–1155.
    1. Grieb P, Kamienowski J, Janisz M, Kuœnierczyk P, Kawiak J, Hoser G, et al. Hematological effects of intermittent 2-hour infusions of cladribine in multiple sclerosis patients: a comparison of 2 dosage patterns. Int J Hematol. 2001;74:421–427.
    1. Soelberg-Sorensen P, Comi G, Cook S, Giovannoni G, Rammohan K, Rieckmann P, et al. Effects of cladribine tablets on haematological profiles in patients with relapsing-remitting multiple sclerosis (RRMS) in the 96 week, phase III, double blind, placebo-controlled CLARITY study. Mult Scler. 2009;15:S137.
    1. Romine JS, Sipe JC, Koziol JA, Zyroff J, Beutler E. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians. 1999;111:35–44.
    1. Merck Serono’s Oral Investigational Treatment Cladribine Tablets for Multiple Sclerosis Significantly Reduced Relapse Rate in Two-Year Phase III Pivotal Trial. URL: . Accessed Feb 10, 2009
    1. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Sorensen P, et al. Clinical outcomes with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study in patients with relapsing-remitting multiple sclerosis. Mult Scler. 2009;15:S136–S137.
    1. Vermersch P, Comi G, Cook S, Giovannoni G, Rammohan K, Rieckmann P, et al. Early onset of effect of treatment with cladribine tablets for relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study. Mult Scler. 2009;15:S249.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅